Prediction model of Gleason score upgrading after radical prostatectomy based on a Bayesian network

Author:

Wang Guipeng1,Wang Xinning1,Du Haotian1,Wang Yaozhong2,Sun Liguo2,Zhang Mingxin1,Li Shengxian1,Jia Yuefeng1,Yang Xuecheng1

Affiliation:

1. The Affiliated Hospital of Qingdao University

2. JuXian People’s Hospital

Abstract

Abstract Objective To explore the clinical value of the Gleason score upgrading (GSU)prediction model after radical prostatectomy (RP) based on a Bayesian network. Methods The data of 356 patients who underwent prostate biopsy and RP in our hospital from January 2018 to May 2021 were retrospectively analysed. Fourteen risk factors,including age, body mass index (BMI), total prostate-specific antigen (tPSA), prostate volume, total prostate-specific antigen density (PSAD), the number and proportion of positive biopsy cores, PI-RADS score, clinical stage and postoperative pathological characteristics, were included in the analysis. Data were used to establish a prediction model for Gleason score elevation based on the tree augmented naive (TAN) Bayesian algorithm. Moreover, the Bayesia Lab validation function was used to calculate the importance of polymorphic Birnbaum according to the results of the posterior analysis and to obtain the importance of each risk factor. ResultsIn the overall cohort, 110 patients (30.89%) had GSU. Based on all of the risk factors that were included in this study, the AUC of the model was 81.06%, and the accuracy was 76.64%. The importance ranking results showed that lymphatic metastasis, the number of positive biopsy cores, ISUP stage and PI-RADS score were the top four influencing factors for GSU after RP. ConclusionsThe prediction model of GSU after RP based on a Bayesian network has high accuracy andcan more accurately evaluate the Gleason score of prostate biopsy specimens and guide treatment decisions.

Publisher

Research Square Platform LLC

Reference25 articles.

1. 1. Sung, H.; Ferlay, J.; Siegel, R. L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca-a Cancer Journal for Clinicians 2021, 71 (3), 209–249.

2. 2. Zheng, R.; Zhang, S.; Zeng, H.; Wang, S.; Sun, K.; Chen, R.; Li, L.; Wei, W.; He, J., Cancer incidence and mortality in China, 2016. Journal of the National Cancer Center 2022, 2 (1), 1–9.

3. 3. Epstein, J.; Egevad, L.; Amin, M.; Delahunt, B.; Srigley, J.; Humphrey, P.;, J. T. A. j. o. s. p., The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. European Journal of Surgical Oncology 2016, 40 (2), 244 − 52.

4. 4. Cohen, M. S.; Hanley, R. S.; Kurteva, T.; Ruthazer, R.; Silverman, M. L.; Sorcini, A.; Hamawy, K.; Roth, R. A.; Tuerk, I.; Libertino, J. A., Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: The Lahey Clinic Medical Center experience and an international meta-analysis. European Urology 2008, 54 (2), 371–381.

5. 5. De Nunzio, C.; Pastore, A. L.; Lombardo, R.; Simone, G.; Leonardo, C.; Mastroianni, R.; Collura, D.; Muto, G.; Gallucci, M.; Carbone, A.; Fuschi, A.; Dutto, L.; Witt, J. H.; De Dominicis, C.; Tubaro, A., The new Epstein gleason score classification significantly reduces upgrading in prostate cancer patients. Eur J Surg Oncol 2018, 44 (6), 835–839.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3